vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Phillips Edison & Company, Inc. (PECO). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $190.7M, roughly 1.5× Phillips Edison & Company, Inc.). Phillips Edison & Company, Inc. runs the higher net margin — 17.4% vs -45.7%, a 63.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 7.0%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 8.7%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Consolidated Edison, Inc., commonly known as Con Edison or ConEd, is an energy company based in New York City. It is one of the largest investor-owned energy companies in the United States, with approximately $15.26 billion in annual revenues as of 2024, and over $70 billion in assets. The company provides a wide range of energy-related products and services to its customers through its subsidiaries:Consolidated Edison Company of New York, Inc. (CECONY), a regulated utility providing electric...
GH vs PECO — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $190.7M |
| Net Profit | $-128.5M | $33.2M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 30.5% |
| Net Margin | -45.7% | 17.4% |
| Revenue YoY | 39.4% | 7.0% |
| Net Profit YoY | -15.8% | 15.1% |
| EPS (diluted) | $-1.01 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $190.7M | ||
| Q4 25 | $281.3M | $187.9M | ||
| Q3 25 | $265.2M | $182.7M | ||
| Q2 25 | $232.1M | $177.8M | ||
| Q1 25 | $203.5M | $178.3M | ||
| Q4 24 | $201.8M | $173.0M | ||
| Q3 24 | $191.5M | $165.5M | ||
| Q2 24 | $177.2M | $161.5M |
| Q1 26 | — | $33.2M | ||
| Q4 25 | $-128.5M | $47.5M | ||
| Q3 25 | $-92.7M | $24.7M | ||
| Q2 25 | $-99.9M | $12.8M | ||
| Q1 25 | $-95.2M | $26.3M | ||
| Q4 24 | $-111.0M | $18.1M | ||
| Q3 24 | $-107.8M | $11.6M | ||
| Q2 24 | $-102.6M | $15.3M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | 30.5% | ||
| Q4 25 | -43.0% | — | ||
| Q3 25 | -37.3% | — | ||
| Q2 25 | -45.9% | — | ||
| Q1 25 | -54.6% | — | ||
| Q4 24 | -62.4% | — | ||
| Q3 24 | -61.3% | — | ||
| Q2 24 | -56.8% | — |
| Q1 26 | — | 17.4% | ||
| Q4 25 | -45.7% | 25.3% | ||
| Q3 25 | -35.0% | 13.5% | ||
| Q2 25 | -43.0% | 7.2% | ||
| Q1 25 | -46.8% | 14.8% | ||
| Q4 24 | -55.0% | 10.5% | ||
| Q3 24 | -56.3% | 7.0% | ||
| Q2 24 | -57.9% | 9.5% |
| Q1 26 | — | $0.24 | ||
| Q4 25 | $-1.01 | $0.38 | ||
| Q3 25 | $-0.74 | $0.20 | ||
| Q2 25 | $-0.80 | $0.10 | ||
| Q1 25 | $-0.77 | $0.21 | ||
| Q4 24 | $-0.90 | $0.16 | ||
| Q3 24 | $-0.88 | $0.09 | ||
| Q2 24 | $-0.84 | $0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $3.1M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $2.3B |
| Total Assets | $2.0B | $5.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $3.1M | ||
| Q4 25 | $378.2M | $3.5M | ||
| Q3 25 | $580.0M | $4.1M | ||
| Q2 25 | $629.1M | $5.6M | ||
| Q1 25 | $698.6M | $5.5M | ||
| Q4 24 | $525.5M | $4.9M | ||
| Q3 24 | $585.0M | $6.4M | ||
| Q2 24 | $933.7M | $7.1M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $2.4B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $1.1B | $2.4B | ||
| Q1 25 | $1.1B | $2.3B | ||
| Q4 24 | $1.1B | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.0B |
| Q1 26 | — | $2.3B | ||
| Q4 25 | $-99.3M | $2.3B | ||
| Q3 25 | $-354.5M | $2.3B | ||
| Q2 25 | $-305.5M | $2.3B | ||
| Q1 25 | $-250.8M | $2.3B | ||
| Q4 24 | $-139.6M | $2.3B | ||
| Q3 24 | $-60.1M | $2.2B | ||
| Q2 24 | $-1.6M | $2.3B |
| Q1 26 | — | $5.4B | ||
| Q4 25 | $2.0B | $5.3B | ||
| Q3 25 | $1.3B | $5.3B | ||
| Q2 25 | $1.3B | $5.3B | ||
| Q1 25 | $1.3B | $5.2B | ||
| Q4 24 | $1.5B | $5.0B | ||
| Q3 24 | $1.5B | $5.0B | ||
| Q2 24 | $1.6B | $4.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.04× | ||
| Q3 25 | — | 1.05× | ||
| Q2 25 | — | 1.04× | ||
| Q1 25 | — | 0.99× | ||
| Q4 24 | — | 0.91× | ||
| Q3 24 | — | 0.94× | ||
| Q2 24 | — | 0.90× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $55.6M |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | 12.6% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $55.6M | ||
| Q4 25 | $-26.4M | $348.1M | ||
| Q3 25 | $-35.4M | $95.4M | ||
| Q2 25 | $-60.3M | $96.1M | ||
| Q1 25 | $-62.7M | $60.5M | ||
| Q4 24 | $-64.5M | $334.7M | ||
| Q3 24 | $-51.1M | $109.1M | ||
| Q2 24 | $-94.0M | $78.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — |
| Q1 26 | — | 12.6% | ||
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — |
| Q1 26 | — | 1.67× | ||
| Q4 25 | — | 7.33× | ||
| Q3 25 | — | 3.87× | ||
| Q2 25 | — | 7.52× | ||
| Q1 25 | — | 2.30× | ||
| Q4 24 | — | 18.45× | ||
| Q3 24 | — | 9.40× | ||
| Q2 24 | — | 5.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PECO
| Rental income | $186.3M | 98% |
| Fees and management income | $3.4M | 2% |
